MENU

Can Glaukos Corporation (GKOS) Stock Reach $280?

an ophthalmic medical device company

A.I.Advisor
published price charts
A.I.Advisor
Nov 15, 2026

Can Glaukos Corporation (GKOS) Stock Reach $280?

Glaukos Corporation (NYSE: GKOS) is an ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. After a third-quarter earnings blowout that sent shares to record highs, the stock now trades above its average analyst price target, making the question of whether it can reach $280 a matter of valuation and continued execution rather than a simple catch-up to Street expectations.

Key Takeaways

  • The $280 objective used here is not an analyst consensus; it is a fallback target drawn from publicly discussed bull-case and upper-bound forecasts (roughly $280–$284), not from the average of brokerage price targets.
  • The stock last traded near $245.72, so reaching $280 would require a gain of about 14%.
  • Among 11 recent 12-month analyst targets, the range was $210 to $255, with an arithmetic mean near $238 — already below the current price.
  • The four targets above the current price (Citi $247, H.C. Wainwright $248, Needham $251, Truist $255) average only about $250, well short of $280.
  • Key supports are surging sales of iDose TR and Epioxa, a raised 2026 outlook, and a preliminary $1 billion 2027 revenue target.
  • The biggest risks are Medicare coverage determinations, a demanding valuation, and heavy operating-expense growth.
  • Readers can track the latest Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading ideas across thousands of stocks and ETFs.

Analyst Price Targets and How the $280 Objective Was Set

Because GKOS has rallied past the average analyst price target, the standard consensus method does not apply. A review of 11 recent 12-month targets shows a low of $210 (Jefferies) and a high of $255 (Truist Financial), with an arithmetic mean of roughly $238. The four targets that still sit above the current price average only about $250, less than 2% above the market and far below a 10% threshold. Accordingly, no meaningful analyst-derived target exists, and the $280 level instead comes from public market commentary: bull-case scenario estimates near $280 and upper-bound forecasts of roughly $283–$284. This is best understood as a valuation- and momentum-based objective, not a Street consensus.

Current Market Position and Path Toward the Target

The stock last traded near $245.72, toward the top of a 52-week range of roughly $73 to $255. Reaching $280 implies about a 14% advance — modest in percentage terms, though it would require a clean break above the stock's all-time highs. The catalyst behind the move is real: third-quarter revenue of $211 million rose 58% year over year, non-GAAP EPS (earnings per share) of $0.47 beat expectations, and management raised full-year 2026 revenue guidance to $775–$785 million while setting a preliminary $1 billion sales goal for 2027. Yet the stock already trades at a high multiple of sales, meaning further upside depends on earnings growth and multiple support, not just revenue.

What Could Support a Move Toward the Target

The two growth drivers are iDose TR, a long-duration glaucoma implant, and Epioxa, the first FDA-approved topical therapy for the corneal disorder keratoconus. Together they powered U.S. glaucoma sales up 47% and corneal health sales up 154% in the third quarter. Gross margin widened to roughly 85% on a GAAP (generally accepted accounting principles) basis, and the company swung to a small quarterly profit. Continued re-acceleration of these launches, expanding reimbursement, and any upward analyst revisions would be the clearest supports for a move toward $280.

What Could Prevent the Target From Being Reached

Medicare Administrative Contractors (MACs) are weighing local coverage determinations that could require patients to try laser treatment and two eye drops before iDose TR is covered, a step-therapy hurdle that management says is already embedded in its $1 billion outlook but remains unresolved. Valuation is also demanding: the stock trades at roughly 13 times projected 2027 sales and a steep forward P/E (price-to-earnings) ratio. Operating expenses are expected to rise about 30% in 2026, and competitive pressure in ophthalmology, including in the demodex blepharitis market, could weigh on sentiment.

Technical Levels and Market Structure

The stock is consolidating just below its record highs after a 30%-plus post-earnings surge. The prior all-time-high zone near $248–$255 now serves as the primary resistance level that must be cleared before $280 becomes reachable. On the downside, the pre-earnings breakout area near $210–$225 is a notable support level. The long-term trend is clearly upward, but the chart is extended after a more than threefold rise from its 52-week low.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month horizon, though the $280 objective discussed publicly has no formal time frame. Investors should monitor quarterly iDose TR and Epioxa sales, fourth-quarter and 2027 guidance, any MAC coverage decisions on iDose TR, Epioxa reimbursement progress, operating-expense discipline, and analyst target revisions. Any downgrade or coverage setback could reset expectations quickly given the premium valuation.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors following volatile growth names like GKOS, the tool offers a structured way to track momentum and potential turning points. Explore the signals to see how AI-driven monitoring can complement your own research process.

Final Assessment

Can GKOS reach $280? The target represents a roughly 14% advance from current levels and is rooted in public bull-case discussion rather than analyst consensus, which sits near $238 and below the market price. The operating story — accelerating iDose TR and Epioxa sales, raised guidance, and a path toward $1 billion in 2027 revenue — is genuinely strong. Against that, a premium valuation, unresolved Medicare coverage questions, and heavy spending leave little room for error. Whether the stock reaches $280 will likely hinge on reimbursement clarity and continued beat-and-raise execution, not on the stock's already-substantial rally.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

GKOS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GKOS
1D Price
Change %
GKOS100%
-4.18%
ISRG - GKOS
51%
Loosely correlated
-2.23%
NTRA - GKOS
48%
Loosely correlated
+0.71%
RDNT - GKOS
48%
Loosely correlated
-4.14%
TWST - GKOS
46%
Loosely correlated
+3.88%
ALGN - GKOS
43%
Loosely correlated
+0.31%
More

Groups containing GKOS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GKOS
1D Price
Change %
GKOS100%
-4.18%
Health Services
category (238 stocks)
6%
Poorly correlated
-3.33%
Medical/Nursing Services
category (138 stocks)
5%
Poorly correlated
-2.46%